If you typed CREOS into a search box, you are probably building a CRO shortlist. This article uses only what CREOS publishes (www.creoscro.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What CREOS publishes
CREOS is a Buenos Aires CRO offering "solutions in clinical research to the pharmaceutical, biotechnology and medical devices industry": Phase I–III, bioequivalence, adaptive, basket and umbrella designs, and real-world evidence. Its co-founders are Daniel Livio, MD, and Néstor Flaster, MD, a former ANMAT evaluator.
CREOS vs bioaccess®
| Dimension | CREOS | bioaccess® |
|---|---|---|
| Core focus | Argentine drug / RWE CRO with devices listed | First-in-human and early feasibility studies for medical devices |
| Geography | See provider site | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | See provider site | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If the study is an Argentine Phase II–III, a bioequivalence study or a real-world evidence project, CREOS fits the brief.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including CREOS, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts from the CREOS public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.
Leave a Reply